U.S. Research & Development Facilities in Waltham/Boston, MA and Princeton, NJ -- GPC Biotech AG (Frankfurt: GPC) (TecDAX 30) (NASDAQ: GPCB) today announced that it had received clearance from the Paul-Ehrlich-Institut (PEI) to initiate human clinical testing in Germany with the 1D09C3 anticancer monoclonal antibody. The PEI is the German national agency responsible for regulating biological and blood products.
